The Asanté™ Rapid HIV-1 Recency (or Incidence) Assay is a rapid blood test version of the Sedia™ HIV-1 LAg-Avidity EIA that differentiates recent from long-term HIV-1 infections and carries a confirmatory indicator to verify HIV-1 reactivity. The most immediate application for this assay, currently in development, is as an HIV-1 incidence assay in the same manner that the Sedia™ HIV-1 LAg-Avidity EIA and the Sedia™ BED HIV-1 Incidence EIA, which also identify recent infections, are used to estimate incidence.
Used with blood (both venous and finger stick), serum, plasma or dried blood spot specimens, the assay will be suitable for population monitoring but also has the potential to be used for identifying recently infected individuals who at elevated risk of disease transmission due to the high viral load typically present in early infections.
The assay is built on the Asanté™ rapid test platform but contains 3 reaction lines (going from top to bottom): a control line to indicate the test is valid and was properly performed, a prevalence or confirmatory line to verify HIV-1 reactivity of the specimen, and an incidence or recency line, which reacts when a specimen is a long-term infection. Results are available in as soon as 20 minutes and can be read visually.
Sedia Biosciences is currently collaborating with the Centers for Disease Control and Prevention (CDC) to develop this assay. |
